Author Correction: Astrocytic Sox9 Overexpression in Alzheimer’s Disease Mouse Models Promotes Aβ Plaque Phagocytosis and Preserves Cognitive Function

Why It Matters

Accurate figure labeling is essential for interpreting Sox9’s impact on Aβ plaque clearance, preventing downstream research errors. The correction safeguards the integrity of neurodegeneration studies that rely on these data.

Key Takeaways

• Fig. 2b y‑axis labels AQP4 and SLC1A2 were swapped
• Human control and Alzheimer labels were misplaced in the original figure
• Corrected figure clarifies astrocyte marker expression across disease states
• Accurate labeling prevents misinterpretation of Sox9’s role in plaque clearance
• Updated PDF/HTML ensures researchers cite the correct data

Pulse Analysis

The original study highlighted that overexpressing the transcription factor Sox9 in astrocytes boosts the brain’s ability to engulf amyloid‑beta plaques, preserving memory in mouse models of Alzheimer’s disease. By enhancing astrocytic phagocytosis, the research suggested a novel therapeutic avenue that could complement existing anti‑amyloid strategies. However, the impact of such findings hinges on precise data presentation, especially when visualizing marker expression that underpins the mechanistic claims.

The recent correction addresses a critical error in Figure 2b, where the y‑axis labels for two key astrocytic proteins—AQP4 and SLC1A2—were inadvertently switched, and the human control versus Alzheimer sample labels were misaligned. Such mislabeling can lead readers to draw opposite conclusions about protein distribution, potentially skewing interpretations of how Sox9 modulates astrocyte function. By rectifying these visual cues, the authors ensure that subsequent citations and meta‑analyses reference the intended expression patterns, preserving the study’s scientific credibility.

Beyond this single paper, the episode underscores a broader challenge in biomedical publishing: the need for rigorous figure verification before release. In fast‑moving fields like neurodegeneration, even minor graphical errors can propagate through grant proposals, drug development pipelines, and clinical trial designs. Journals and research teams are increasingly adopting automated checks and post‑publication review mechanisms to catch such issues early. The corrected figure now serves as a reliable reference point for investigators exploring astrocyte‑targeted interventions, reinforcing the importance of meticulous data stewardship in advancing Alzheimer’s therapeutics.